<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet href="/rss.css" type="text/css"?>
<rdf:RDF xmlns="http://purl.org/rss/1.0/"
    xmlns:cc="http://web.resource.org/cc/"
    xmlns:dc="http://purl.org/dc/elements/1.1/"
    xmlns:extra="http://www.w3.org/1999/xhtml"
    xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/"
    xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#">
    <channel rdf:about="http://www.biomedcentral.com/feeds/mostaccessed/journal?journal=bmccomplementalternmed&amp;quantity=&amp;format=rss&amp;version=">
        <title>BMC Complementary and Alternative Medicine - Most accessed articles</title>
        <link>http://www.biomedcentral.com/bmccomplementalternmed/</link>
        <description>The most accessed research articles published by BMC Complementary and Alternative Medicine</description>
        <dc:date>2009-11-17T00:00:00Z</dc:date>
        <items>
            <rdf:Seq>
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1472-6882/6/39" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1472-6882/9/41" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1472-6882/9/42" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1472-6882/9/38" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1472-6882/9/6" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1472-6882/9/34" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1472-6882/9/45" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1472-6882/9/27" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1472-6882/6/35" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1472-6882/9/40" />
                            </rdf:Seq>
        </items>
        <extra:info rdf:parseType="Literal">
            <html:div style="font:14px Verdana, Geneva, Arial, Helvetica, sans-serif" xmlns:html="http://www.w3.org/1999/xhtml">
                <html:span style="font-weight:bold">
                    This is an RSS newsfeed from BioMed Central
                </html:span>
                <html:br />
                <html:span style="font-size: 12px;">
                    It is intended to be used with an RSS reader. For more information about RSS newsfeeds from BioMed Central, visit
                    <html:br />
                    <html:a href="http://www.biomedcentral.com/info/about/rss/" style="color:#3333CC; font-size:12px;">
                        http://www.biomedcentral.com/info/about/rss/
                    </html:a>
                    <html:br />
                </html:span>
            </html:div>
        </extra:info>
        <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </channel>
        <item rdf:about="http://www.biomedcentral.com/1472-6882/6/39">
        <title>In vitroantibacterial activity of some plant essential oils</title>
        <description>Background:To evaluate the antibacterial activity of 21 plant essential oils against six bacterial species.Methods:The selected essential oils were screened against four gram-negative bacteria (Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Proteus vulgaris) and two gram-positive bacteria Bacillus subtilis and Staphylococcus aureus at four different concentrations (1:1, 1:5, 1:10 and 1:20) using disc diffusion method. The MIC of the active essential oils were tested using two fold agar dilution method at concentrations ranging from 0.2 to 25.6 mg/ml.Results:Out of 21 essential oils tested, 19 oils showed antibacterial activity against one or more strains. Cinnamon, clove, geranium, lemon, lime, orange and rosemary oils exhibited significant inhibitory effect. Cinnamon oil showed promising inhibitory activity even at low concentration, whereas aniseed, eucalyptus and camphor oils were least active against the tested bacteria. In general, B. subtilis was the most susceptible. On the other hand, K. pneumoniae exhibited low degree of sensitivity.Conclusion:Majority of the oils showed antibacterial activity against the tested strains. However Cinnamon, clove and lime oils were found to be inhibiting both gram-positive and gram-negative bacteria. Cinnamon oil can be a good source of antibacterial agents.</description>
        <link>http://www.biomedcentral.com/1472-6882/6/39</link>
                <dc:creator>Seenivasan Prabuseenivasan</dc:creator>
                <dc:creator>Manickkam Jayakumar</dc:creator>
                <dc:creator>Savarimuthu Ignacimuthu</dc:creator>
                <dc:source>BMC Complementary and Alternative Medicine 2006, 6:39</dc:source>
        <dc:date>2006-11-30T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1472-6882-6-39</dc:identifier>
        <prism:publicationName>BMC Complementary and Alternative Medicine</prism:publicationName>
        <prism:issn>1472-6882</prism:issn>
        <prism:volume>6</prism:volume>
        <prism:startingPage>39</prism:startingPage>
        <prism:publicationDate>2006-11-30T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1472-6882/9/41">
        <title>Use of complementary and alternative medicine: a survey in Turkish gastroenterology patients.</title>
        <description>Background:
The study examined complementary and alternative medicine (CAM) usage by patients attending a Turkish gastroenterology outpatient clinic.
Methods:
The survey was conducted on 216 patients presenting with gastrointestinal problems during their first visit to the clinic using a 31 item, self-report questionnaire between May and October 2005. Data included information on patient demographics and their gastrointestinal symptoms, as well as items to identify CAM use and patient satisfaction with these therapies.
Results:
Seventy-nine patients (36.6%) reported using one or more forms of CAM. The most commonly used therapy was herbal therapy, usually taken as a tea or infusion. These were used by 27 people (29%) in this subgroup. Common indicators for their use were epigastric pain, constipation, bloating and dyspepsia or indigestion. CAM use among upper GI patients was marginally higher than lower GI patients (41.8% versus 41.2%), but the highest usage was amongst patients with liver disease where 53.8% reported using one or more CAM therapy. About half of the patients learned about CAM from their relatives or friends, with more women than men using the therapies (p &lt; 0.05). Clinical characteristics such as diagnosis, duration of symptoms and prior surgical intervention did not differ between users and non-users of CAM therapies. Multivariate analysis showed that being female and higher educational status were positively associated with CAM usage (p &lt; 0.05).
Conclusion:
CAM usage in our sample of gastrointestinal patients was lower than that described in other countries and other chronic disease groups. This could be due to their low perceived efficacy, or the relatively transient duration of symptoms experienced by the sample. Healthcare professionals need however, to be aware of CAM usage in order to educate patients appropriately about possible adverse effects or drug-interactions.</description>
        <link>http://www.biomedcentral.com/1472-6882/9/41</link>
                <dc:creator>Taylan Kav</dc:creator>
                <dc:source>BMC Complementary and Alternative Medicine 2009, 9:41</dc:source>
        <dc:date>2009-10-26T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1472-6882-9-41</dc:identifier>
        <prism:publicationName>BMC Complementary and Alternative Medicine</prism:publicationName>
        <prism:issn>1472-6882</prism:issn>
        <prism:volume>9</prism:volume>
        <prism:startingPage>41</prism:startingPage>
        <prism:publicationDate>2009-10-26T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1472-6882/9/42">
        <title>Self-medication with over-the-counter drugs and complementary medications in South Australia&apos;s elderly population</title>
        <description>Background:
A number of surveys have examined use of complementary and alternative medicines (CAM) in Australia. However, there are limited Australian data on use of CAM and over-the-counter (OTC) medicines in the elderly population. The main aims of this study were to examine self-medication practices with CAM and OTC medicines among older Australians and variables associated with their use.
Methods:
The Australian Longitudinal Study of Ageing (ALSA) is an ongoing multidisciplinary prospective study of the older population which commenced in 1992 in South Australia. Data collected in 4 waves of ALSA between 1992 and 2004 were used in this study with a baseline sample of 2087 adults aged 65 years and over, living in the community or residential aged care. OTC medicines were classified according to the World Health Organization Anatomical Therapeutic Chemical (ATC) classification. CAM were classified according a modified version of the classification adopted by the Therapeutics Goods Administration (TGA) in Australia.
Results:
The prevalence of CAM or OTC use ranged from 17.7% in 2000-2001 to 35.5% in 2003-2004. The top classes of CAM and OTC medicines used remained relatively constant over the study period. The most frequent classes of CAM used were vitamins and minerals, herbal medicines and nutritional supplements while the most commonly used OTC were analgesics, laxatives and low dose aspirin. Females and those of younger age were more likely to be CAM users but no variable was associated with OTC use.
Conclusion:
Participants seemed to self-medicate in accordance with approved indications, suggesting they were informed consumers, actively looking after their own health. However, use of analgesics and aspirin are associated with an increased risk of adverse drug events in the elderly. Future work should examine how self-medication contributes to polypharmacy and increases the risk of adverse drug reactions.</description>
        <link>http://www.biomedcentral.com/1472-6882/9/42</link>
                <dc:creator>Lynn Yeen Goh</dc:creator>
                <dc:creator>Agnes Vitry</dc:creator>
                <dc:creator>Susan Semple</dc:creator>
                <dc:creator>Adrian Esterman</dc:creator>
                <dc:creator>Mary Luszcz</dc:creator>
                <dc:source>BMC Complementary and Alternative Medicine 2009, 9:42</dc:source>
        <dc:date>2009-11-11T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1472-6882-9-42</dc:identifier>
        <prism:publicationName>BMC Complementary and Alternative Medicine</prism:publicationName>
        <prism:issn>1472-6882</prism:issn>
        <prism:volume>9</prism:volume>
        <prism:startingPage>42</prism:startingPage>
        <prism:publicationDate>2009-11-11T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1472-6882/9/38">
        <title>Evaluation and implications of natural product use in preoperative patients:  a retrospective review</title>
        <description>Background:
Medication Reconciliation and Medication Safety are two themes emphasized in a variety of healthcare organizations. As a result, health care facilities have established methods for obtaining a patient&apos;s medication history. However, these methods may vary among institutions or even among the health care professionals in a single institution, and studies have shown that patients are reluctant to disclose their complementary and alternative medicine use to any health care professional. This lack of disclosure is important in surgical patients because of potential herbal interactions with medications and drugs used during the surgical procedure; and the potential for adverse reactions including effects on coagulation, blood pressure, sedation, electrolytes or diuresis. Therefore, the objectives of this study are to identify patterns of natural product use, to identify potential complications among patients scheduled for surgery, to improve existing medication reconciliation efforts, and to develop discontinuation guidelines for the use of these products prior to surgery.
Methods:
A retrospective review of surgery patients presenting to the Anesthesia Preoperative Evaluation Clinic (APEC) at the University of Kansas Hospital was conducted to identify the prevalence of natural product use. The following data was collected: patient age; gender; allergy information; date of medication history; number of days prior to surgery; source of medication history; credentials of person obtaining the history; number and name of prescription medications, over-the-counter medications and natural products; and natural product dosage. Following the collection of data and analysis of the most common natural products used, possible complications and interactions were identified, and a protocol regarding the pre-operative use of natural products was developed and implemented.
Results:
Approximately one-fourth of patients seen in the APEC indicated the use of natural products. Patients taking natural products were significantly older, were more likely to undergo cardiac or chest surgery, and were more likely to be taking more prescription and non-prescription medications (all p &lt; 0.001).
Conclusion:
Based on the results of this study, it is concluded that there is a need for established guidelines regarding discontinuation of selected natural products prior to surgery and further education is needed concerning the perioperative implications of natural products.</description>
        <link>http://www.biomedcentral.com/1472-6882/9/38</link>
                <dc:creator>Allison King</dc:creator>
                <dc:creator>Flint Russett</dc:creator>
                <dc:creator>Joyce Generali</dc:creator>
                <dc:creator>Dennis Grauer</dc:creator>
                <dc:source>BMC Complementary and Alternative Medicine 2009, 9:38</dc:source>
        <dc:date>2009-10-13T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1472-6882-9-38</dc:identifier>
        <prism:publicationName>BMC Complementary and Alternative Medicine</prism:publicationName>
        <prism:issn>1472-6882</prism:issn>
        <prism:volume>9</prism:volume>
        <prism:startingPage>38</prism:startingPage>
        <prism:publicationDate>2009-10-13T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1472-6882/9/6">
        <title>Frankincense oil derived from Boswellia carteri induces tumor cell specific cytotoxicity</title>
        <description>Background:
Originating from Africa, India, and the Middle East, frankincense oil has been important both socially and economically as an ingredient in incense and perfumes for thousands of years. Frankincense oil is prepared from aromatic hardened gum resins obtained by tapping Boswellia trees. One of the main components of frankincense oil is boswellic acid, a component known to have anti-neoplastic properties. The goal of this study was to evaluate frankincense oil for its anti-tumor activity and signaling pathways in bladder cancer cells.
Methods:
Frankincense oil-induced cell viability was investigated in human bladder cancer J82 cells and immortalized normal bladder urothelial UROtsa cells. Temporal regulation of frankincense oil-activated gene expression in bladder cancer cells was identified by microarray and bioinformatics analysis.
Results:
Within a range of concentration, frankincense oil suppressed cell viability in bladder transitional carcinoma J82 cells but not in UROtsa cells. Comprehensive gene expression analysis confirmed that frankincense oil activates genes that are responsible for cell cycle arrest, cell growth suppression, and apoptosis in J82 cells. However, frankincense oil-induced cell death in J82 cells did not result in DNA fragmentation, a hallmark of apoptosis.
Conclusion:
Frankincense oil appears to distinguish cancerous from normal bladder cells and suppress cancer cell viability. Microarray and bioinformatics analysis proposed multiple pathways that can be activated by frankincense oil to induce bladder cancer cell death. Frankincense oil might represent an alternative intravesical agent for bladder cancer treatment.</description>
        <link>http://www.biomedcentral.com/1472-6882/9/6</link>
                <dc:creator>Mark Barton Frank</dc:creator>
                <dc:creator>Qing Yang</dc:creator>
                <dc:creator>Jeanette Osban</dc:creator>
                <dc:creator>Joseph Azzarello</dc:creator>
                <dc:creator>Marcia Saban</dc:creator>
                <dc:creator>Ricardo Saban</dc:creator>
                <dc:creator>Richard Ashley</dc:creator>
                <dc:creator>Jan Welter</dc:creator>
                <dc:creator>Kar-Ming Fung</dc:creator>
                <dc:creator>Hsueh-Kung Lin</dc:creator>
                <dc:source>BMC Complementary and Alternative Medicine 2009, 9:6</dc:source>
        <dc:date>2009-03-18T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1472-6882-9-6</dc:identifier>
        <prism:publicationName>BMC Complementary and Alternative Medicine</prism:publicationName>
        <prism:issn>1472-6882</prism:issn>
        <prism:volume>9</prism:volume>
        <prism:startingPage>6</prism:startingPage>
        <prism:publicationDate>2009-03-18T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1472-6882/9/34">
        <title>The antibacterial properties of Malaysian tualang honey against wound and enteric microorganisms in comparison to manuka honey</title>
        <description>Background:
Antibiotic resistance of bacteria is on the rise, thus the discovery of alternative therapeutic agents is urgently needed. Honey possesses therapeutic potential, including wound healing properties and antimicrobial activity. Although the antimicrobial activity of honey has been effectively established against an extensive spectrum of microorganisms, it differs depending on the type of honey. To date, no extensive studies of the antibacterial properties of tualang (Koompassia excelsa) honey on wound and enteric microorganisms have been conducted. The objectives of this study were to conduct such studies and to compare the antibacterial activity of tualang honey with that of manuka honey.
Methods:
Using a broth dilution method, the antibacterial activity of tualang honey against 13 wound and enteric microorganisms was determined; manuka honey was used as the control. Different concentrations of honey [6.25-25% (w/v)] were tested against each type of microorganism. Briefly, two-fold dilutions of honey solutions were tested to determine the minimum inhibitory concentration (MIC) against each type of microorganism, followed by more assays within a narrower dilution range to obtain more precise MIC values. MICs were determined by both visual inspection and spectrophotometric assay at 620 nm. Minimum bactericidal concentration (MBC) also was determined by culturing on blood agar plates.
Results:
By visual inspection, the MICs of tualang honey ranged from 8.75% to 25% compared to manuka honey (8.75-20%). Spectrophotometric readings of at least 95% inhibition yielded MIC values ranging between 10% and 25% for both types of honey. The lowest MBC for tualang honey was 20%, whereas that for manuka honey was 11.25% for the microorganisms tested. The lowest MIC value (8.75%) for both types of honey was against Stenotrophomonas maltophilia. Tualang honey had a lower MIC (11.25%) against Acinetobacter baumannii compared to manuka honey (12.5%).
Conclusion:
Tualang honey exhibited variable activities against different microorganisms, but they were within the same range as those for manuka honey. This result suggests that tualang honey could potentially be used as an alternative therapeutic agent against certain microorganisms, particularly A. baumannii and S. maltophilia.</description>
        <link>http://www.biomedcentral.com/1472-6882/9/34</link>
                <dc:creator>Hern Tze Tan</dc:creator>
                <dc:creator>Rosliza Abdul Rahman</dc:creator>
                <dc:creator>Siew Hua Gan</dc:creator>
                <dc:creator>Ahmad Sukari Halim</dc:creator>
                <dc:creator>Siti Asma' Hassan</dc:creator>
                <dc:creator>Siti Amrah Sulaiman</dc:creator>
                <dc:creator>Kirnpal-Kaur S</dc:creator>
                <dc:source>BMC Complementary and Alternative Medicine 2009, 9:34</dc:source>
        <dc:date>2009-09-15T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1472-6882-9-34</dc:identifier>
        <prism:publicationName>BMC Complementary and Alternative Medicine</prism:publicationName>
        <prism:issn>1472-6882</prism:issn>
        <prism:volume>9</prism:volume>
        <prism:startingPage>34</prism:startingPage>
        <prism:publicationDate>2009-09-15T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1472-6882/9/45">
        <title>Bee products prevent VEGF-induced angiogenesis in human umbilical vein endothelial cells</title>
        <description>Background:
Vascular endothelial growth factor (VEGF) is a key regulator of pathogenic angiogenesis in diseases such as cancer and diabetic retinopathy.  Bee products [royal jelly (RJ), bee pollen, and Chinese red propolis] from the honeybee, Apis mellifera, have been used as traditional health foods for centuries.  The aim of this study was to investigate the anti-angiogenic effects of bee products using human umbilical vein endothelial cells (HUVECs).
Methods:
In an in vitro tube formation assay, HUVECs and fibroblast cells were incubated for 14 days with VEGF and various concentrations of bee products [RJ, ethanol extract of bee pollen, ethanol extract of Chinese red propolis and its constituent, caffeic acid phenethyl ester (CAPE)].  To clarify the mechanism of in vitro angiogenesis, HUVEC proliferation and migration were induced by VEGF with or without various concentrations of RJ, bee pollen, Chinese red propolis, and CAPE.
Results:
RJ, bee pollen, Chinese red propolis, and CAPE significantly suppressed VEGF-induced in vitro tube formation in the descending order: CAPE &gt; Chinese red propolis &gt;&gt; bee pollen &gt; RJ.  RJ and Chinese red propolis suppressed both VEGF-induced HUVEC proliferation and migration.  In contrast, bee pollen and CAPE suppressed only the proliferation.
Conclusions:
Among the bee products, Chinese red propolis and CAPE in particular showed strong suppressive effects against VEGF-induced angiogenesis.  These findings indicate that Chinese red propolis and CAPE may have potential as preventive and therapeutic agents against angiogenesis-related human diseases.</description>
        <link>http://www.biomedcentral.com/1472-6882/9/45</link>
                <dc:creator>Hiroshi Izuta</dc:creator>
                <dc:creator>Masamitsu Shimazawa</dc:creator>
                <dc:creator>Kazuhiro Tsuruma</dc:creator>
                <dc:creator>Yoko Araki</dc:creator>
                <dc:creator>Satoshi Mishima</dc:creator>
                <dc:creator>Hideaki Hara</dc:creator>
                <dc:source>BMC Complementary and Alternative Medicine 2009, 9:45</dc:source>
        <dc:date>2009-11-17T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1472-6882-9-45</dc:identifier>
        <prism:publicationName>BMC Complementary and Alternative Medicine</prism:publicationName>
        <prism:issn>1472-6882</prism:issn>
        <prism:volume>9</prism:volume>
        <prism:startingPage>45</prism:startingPage>
        <prism:publicationDate>2009-11-17T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1472-6882/9/27">
        <title>Anti-collagenase, anti-elastase and anti-oxidant activities of extracts from 21 plants </title>
        <description>Background:
Owing to their roles in tissue remodelling in health and disease, several studies have reported investigations on plant extracts as inhibitors of proteinases and as anti-oxidants.
Methods:
The anti-ageing and anti-oxidant properties of 23 plant extracts (from 21 plant species) were assessed as anti-elastase and anti-collagenase activities and in selected anti-oxidant assays along with phenolic content.
Results:
Anti-elastase activities were observed for nine of the extracts with inhibitory activity in the following order: white tea (~89%), cleavers (~58%), burdock root (~51%), bladderwrack (~50%), anise and angelica (~32%). Anti-collagenase activities were exhibited by sixteen plants of which the highest activity was seen in white tea (~87%), green tea (~47%), rose tincture (~41%), and lavender (~31%). Nine plant extracts had activities against both elastase (E) and collagenase (C) and were ranked in the order of white tea (E:89%, C:87%) &gt; bladderwrack (E:50%, C:25%) &gt; cleavers (E:58%, C:7%) &gt; rose tincture (E:22%, C:41%) &gt; green tea (E:10%: C:47%) &gt; rose aqueous (E: 24%, C:26%) &gt; angelica (E:32%, C:17%) &gt; anise (E:32%, C:6%) &gt; pomegranate (E:15%, C:11%).Total phenolic content varied between 0.05 and 0.26 mg gallic acid equivalents (GAE)/mL with the exception of white tea (0.77 mg GAE/mL). For anti-oxidant assessment, the Trolox equivalent anti-oxidant capacity (TEAC) assay revealed activity for all extracts. White tea had the highest activity equivalent to ~21 &#956;M Trolox for a 6.25 &#956;g aliquot. In addition, seven extracts exhibited activities = 10 &#956;M Trolox with witch hazel (6.25 &#956;g = 13 &#956;M Trolox) and rose aqueous (6.25 &#956;g = 10 &#956;M Trolox) showing very high activities at low concentrations. A high activity for white tea was also found in the superoxide dismutase (SOD) assay in which it exhibited ~88% inhibition of reduction of nitroblue tetrazolium. High activities were also observed for green tea (86.41%), rose tincture (82.77%), witch hazel (82.05%) and rose aqueous (73.86%).
Conclusion:
From a panel of twenty three plant extracts, some one dozen exhibit high or satisfactory anti-collagenase or anti-elastase activities, with nine having inhibitory activity against both enzymes. These included white tea which was found to have very high phenolic content, along with high TEAC and SOD activities.</description>
        <link>http://www.biomedcentral.com/1472-6882/9/27</link>
                <dc:creator>Tamsyn Thring</dc:creator>
                <dc:creator>Pauline Hili</dc:creator>
                <dc:creator>Declan Naughton</dc:creator>
                <dc:source>BMC Complementary and Alternative Medicine 2009, 9:27</dc:source>
        <dc:date>2009-08-04T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1472-6882-9-27</dc:identifier>
        <prism:publicationName>BMC Complementary and Alternative Medicine</prism:publicationName>
        <prism:issn>1472-6882</prism:issn>
        <prism:volume>9</prism:volume>
        <prism:startingPage>27</prism:startingPage>
        <prism:publicationDate>2009-08-04T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1472-6882/6/35">
        <title>Antimicrobial activity of some ethnomedicinal plants used by Paliyar tribe from Tamil Nadu, India</title>
        <description>Background:
Antimicrobial activity of 18 ethnomedicinal plant extracts were evaluated against nine bacterial strains (Bacillus subtilis, Staphylococcus aureus, Staphylococcus epidermidis, Enterococcus faecalis, Escherichia coli, Klebsiella pneumonia, Pseudomonas aeruginosa, Ervinia sp, Proteus vulgaris) and one fungal strain (Candida albicans). The collected ethnomedicinal plants were used in folk medicine in the treatment of skin diseases, venereal diseases, respiratory problems and nervous disorders.
Methods:
Plants were collected from Palni hills of Southern Western Ghats and the ethnobotanical data were gathered from traditional healers who inhabit the study area. The hexane and methanol extracts were obtained by cold percolation method and the antimicrobial activity was found using paper disc diffusion method. All microorganisms were obtained from Christian Medical College, Vellore, Tamil Nadu, India.
Results:
The results indicated that out of 18 plants, 10 plants exhibited antimicrobial activity against one or more of the tested microorganisms at three different concentrations of 1.25, 2.5 and 5 mg/disc. Among the plants tested, Acalypha fruticosa, Peltophorum pterocarpum, Toddalia asiatica,Cassia auriculata, Punica granatum and Syzygium lineare were most active. The highest antifungal activity was exhibited by methanol extract of Peltophorum pterocarpum and Punica granatum against Candida albicans.
Conclusion:
This study evaluated the antimicrobial activity of the some ethnomedicinal plants used in folkloric medicine. Compared to hexane extract, methanol extract showed significant activity against tested organisms. This study also showed that Toddalia asiatica, Syzygium lineare, Acalypha fruticosa and Peltophorum pterocarpum could be potential sources of new antimicrobial agents.</description>
        <link>http://www.biomedcentral.com/1472-6882/6/35</link>
                <dc:creator>Veeramuthu Duraipandiyan</dc:creator>
                <dc:creator>Muniappan Ayyanar</dc:creator>
                <dc:creator>Savarimuthu Ignacimuthu</dc:creator>
                <dc:source>BMC Complementary and Alternative Medicine 2006, 6:35</dc:source>
        <dc:date>2006-10-17T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1472-6882-6-35</dc:identifier>
        <prism:publicationName>BMC Complementary and Alternative Medicine</prism:publicationName>
        <prism:issn>1472-6882</prism:issn>
        <prism:volume>6</prism:volume>
        <prism:startingPage>35</prism:startingPage>
        <prism:publicationDate>2006-10-17T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1472-6882/9/40">
        <title>Traditional eye medicine use by newly presenting ophthalmic patients to a teaching hospital in South-eastern Nigeria: socio-demographic and clinical correlates</title>
        <description>Background:
This study set out to determine the incidence, socio-demographic, and clinical correlates of Traditional Eye Medicine (TEM) use in a population of newly presenting ophthalmic outpatients attending a tertiary eye care centre in south-eastern Nigeria.
Methods:
In a comparative cross-sectional survey at the eye clinic of the University of Nigeria Teaching Hospital (UNTH), Enugu, between August 2004 - July 2006, all newly presenting ophthalmic outpatients were recruited. Participants&apos; socio-demographic and clinical data and profile of TEM use were obtained from history and examination of each participant and entered into a pretested questionnaire and proforma. Participants were subsequently categorized into TEM- users and non-users; intra-group analysis yielded proportions, frequencies, and percentages while chi-square test was used for inter-group comparisons at P = 0.01, df = 1.
Results:
Of the 2,542 (males, 48.1%; females, 51.9%) participants, 149 (5.9%) (males, 45%; females, 55%) used TEM for their current eye disease. The TEMs used were chemical substances (57.7%), plant products (37.7%), and animal products (4.7%). They were more often prescribed by non-traditional (66.4%) than traditional (36.9%) medicine practitioners. TEMs were used on account of vision loss (58.5%), ocular itching (25.4%) and eye discharge (3.8%). Reported efficacy from previous users (67.1%) and belief in potency (28.2%) were the main reasons for using TEM. Civil servants (20.1%), farmers (17.7%), and traders (14.1%) were the leading users of TEM. TEM use was significantly associated with younger age (p &lt; 0.01), being married (p &lt; 0.01), rural residence (p &lt; 0.01), ocular anterior segment disease (p &lt; 0.01), delayed presentation (p &lt; 0.01), low presenting visual acuity (p &lt; 0.01), and co-morbid chronic medical disease (p &lt; 0.01), but not with gender (p = 0.157), and educational status (p = 0.115).
Conclusion:
The incidence of TEM use among new ophthalmic outpatients at UNTH is low. The reasons for TEM use are amenable to positive change through enhanced delivery of promotive, preventive, and curative public eye care services. This has implications for eye care planners and implementers. To reverse the trend, we suggest strengthening of eye care programmes, even distribution of eye care resources, active collaboration with orthodox eye care providers and traditional medical practitioners, and intensification of research efforts into the pharmacology of TEMs.</description>
        <link>http://www.biomedcentral.com/1472-6882/9/40</link>
                <dc:creator>Boniface Eze</dc:creator>
                <dc:creator>Chimdi Chuka-Okosa</dc:creator>
                <dc:creator>Judith Uche</dc:creator>
                <dc:source>BMC Complementary and Alternative Medicine 2009, 9:40</dc:source>
        <dc:date>2009-10-24T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1472-6882-9-40</dc:identifier>
        <prism:publicationName>BMC Complementary and Alternative Medicine</prism:publicationName>
        <prism:issn>1472-6882</prism:issn>
        <prism:volume>9</prism:volume>
        <prism:startingPage>40</prism:startingPage>
        <prism:publicationDate>2009-10-24T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <cc:License rdf:about="http://creativecommons.org/licenses/by/2.0/">
        <cc:permits rdf:resource="http://creativecommons.org/ns#Reproduction" />
        <cc:permits rdf:resource="http://creativecommons.org/ns#Distribution" />
        <cc:permits rdf:resource="http://creativecommons.org/ns#DerivativeWorks" />
    </cc:License>
</rdf:RDF>
